# Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer)

> **NCT00359450** · PHASE2 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 186 (—)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** BMS-275183 (oral taxane)

## Key facts

- **NCT ID:** NCT00359450
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-07
- **Primary completion:** 2007-03
- **Final completion:** —
- **Target enrollment:** 186 (—)
- **Last updated:** 2010-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00359450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00359450, "Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00359450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*